📝 Omkar Pharmachem Ltd — results explained
Quarter ended June 2026 (Q1 FY27)
Omkar Pharmachem Ltd reported revenue of ₹0 crore for the quarter ended June 2026 (Q1 FY27), down 35.7% from ₹0 crore in the same quarter last year, and flat sequentially over the March 2026 quarter.
The company reported a net loss of ₹0 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.01.
Operating profit stood at ₹-0 crore — an operating margin (OPM) of -10.7%, compared with 28.6% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Omkar Pharmachem Ltd posted revenue of ₹0 crore, a decline of 14.3% over FY25, with a net profit of ₹0 crore (down 35.0% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹0 crore with a net profit of ₹0 crore.
Valuation snapshot
At the current price of ₹7.60, 532167 has a market capitalisation of ₹8 crore and a trailing P/E of about 85.1.
Within the Commodity Chemicals industry, it is the 25th-largest of the 50 companies we track by market value.
Shareholding pattern
As of Mar 2026, promoters held 0.03%, public shareholders 99.97% of Omkar Pharmachem Ltd.